Flecher E, Joudinaud T, Grinda J-M
Service de chirurgie cardiovasculaire, hôpital européen Georges-Pompidou, 20-40, rue Leblanc, 75015 Paris, France.
Ann Chir. 2006 Oct;131(8):473-8. doi: 10.1016/j.anchir.2005.12.009. Epub 2006 Jan 13.
The impact of heart failure on patients and economical burden on health insurance resources is increasing. Cardiac transplantation is still the primary treatment for patients who are in end stage heart failure. The development of artificial hearts (total and partial) was implemented by the discrepancy between the scarcity of available donors and the importance of waiting lists for cardiac transplantation. The technical progresses achieved since the first works of Kolff in 1957 now allow these patients to have their circulation restored and go home to wait for their transplantation. The encouraging results of the artificial heart and the miniaturization of these devices allow them to be considered as a possible destination therapy for patients not eligible for cardiac transplantation.
心力衰竭对患者的影响以及对健康保险资源的经济负担正在增加。心脏移植仍然是终末期心力衰竭患者的主要治疗方法。由于可用供体稀缺与心脏移植等待名单的重要性之间存在差异,人工心脏(全人工心脏和部分人工心脏)得以发展。自1957年科尔夫首次开展相关工作以来所取得的技术进步,现在使这些患者能够恢复血液循环并回家等待移植。人工心脏令人鼓舞的结果以及这些设备的小型化,使其被视为不适于心脏移植患者的一种可能的目标治疗手段。